|
Jul 30
|
[Latest] Global Lenacapavir Injection Market Size/Share Worth USD 5.68 Billion by 2034 at a 5.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
|
|
Jul 25
|
GM Is Loading Up on Its Own Shares. Investors Should Follow Suit.
|
|
Jul 24
|
Bausch Health Announces the Appointment of Two New Members to Its Board of Directors
|
|
Jul 24
|
Novo Nordisk defeated in Wegovy patent dispute by Viatris
|
|
Jul 23
|
What to Expect From Viatris' Next Quarterly Earnings Report
|
|
Jul 21
|
VTRS Down on Late-Stage Study Failure of Eye Disease Drug
|
|
Jul 21
|
Viatris’ blepharitis ointment fails Phase III trial
|
|
Jul 18
|
Viatris Stock Slides After Phase 3 Blepharitis Drug Trial Misses Key Target
|
|
Jul 18
|
Why Viatris (VTRS) Stock Is Falling Today
|
|
Jul 18
|
Major Market Benchmarks Stabilize After Clinching Record Highs, Driving Muted Premarket Action for US Equity Futures
|
|
Jul 18
|
Viatris Stock Tumbles as Eyelid Inflammation Treatment Misses Target
|
|
Jul 18
|
Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis
|
|
Jul 17
|
Viatris (VTRS) Announces Positive Top-line Results from VEGA-3
|
|
Jul 17
|
Q1 Earnings Highs And Lows: Viatris (NASDAQ:VTRS) Vs The Rest Of The Generic Pharmaceuticals Stocks
|
|
Jul 15
|
Viatris Gains China Approval for COPD Drug Yupelri, Triggers $7.5M Payment to Theravance BioPharma
|
|
Jul 15
|
Viatris Certified as a Great Place to Work® in Canada
|
|
Jul 12
|
Goldman Sachs Reiterates a Hold Rating on Viatris (VTRS) With a $10 PT
|
|
Jun 27
|
The 5 Most Interesting Analyst Questions From Viatris’s Q1 Earnings Call
|
|
Jun 27
|
Viatris gains China approval for Yupelri to treat COPD
|
|
Jun 27
|
Viatris’ presbyopia drug clears second Phase III trial
|